Framing: examine the complete handoff from prescription to patient use. FDA has reported dosing errors involving compounded injectable semaglutide, including confusion over concentrations and measurement. It has also received complaints about compounded GLP-1 shipments arriving warm or inadequately refrigerated. (fda.gov)
Put to: Michael Ganio and Robert Kushner.
Buyer owner: Medical director and pharmacy operations lead.
Why it matters: The contract and workflow should identify who responds when a delivered medicine cannot confidently be accepted or the instructions do not match the prescribed product.
A good answer should cover:
- Product-specific storage requirements and shipping qualification, including seasonal and destination variation.
- The evidence and qualified decision-maker needed to assess a suspected temperature excursion.
- Consistency among prescribed dose, concentration, label, supplied administration device and patient instructions.
- A controlled process for concentration or presentation changes, rather than silent substitution.
- Complaint triage, replacement authorisation, adverse-event escalation and cost allocation.
Follow-up that tests the answer: “A patient reports a warm parcel and unfamiliar instructions on Friday evening. Who answers, what information is gathered, and who makes the clinical decision?”
Evidence to request: A redacted label-and-instructions pack, handling procedures, exception workflow and documented escalation exercise. Do not treat a delivery scan as proof that the product is suitable for use.
Expert quote — reserved: ________________________________________
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded